bullish
Newron Pharmaceuticals - Sarizotan fails to shine
SUMMARY
On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary endpoints. The company will focus now on its novel schizophrenia drug, Evenamide. This clinical programme, due to resume in 2020, is on hold due to COVID-19. Newron drew a €7.5m EIB loan on 15 April and had €39m in cash in December 2019.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Newron Pharmaceuticals - Sarizotan fails to shine05 May 2020
x